Germantown, Maryland, and Hilden, Germany, March 5th, 2018 – QIAGEN today announced the European launch of the artus T. vaginalis QS-RGQ Kit, a CE-marked molecular diagnostic test for the qualitative detection of the protozoan parasite T. vaginalis in both female and male patients. The artus T. vaginalis QS-RGQ Kit is an in vitro real-time polymerase... Read more
BILLERICA, Mass., March 1, 2018 /PRNewswire/ — Bruker today announced the appointment of Dr. Burkhard Prause, the President of the Bruker Energy & Supercon Technologies (BEST) segment, as an executive officer of Bruker Corporation. Dr. Prause has a successful track record of leading BEST through a significant expansion of its business in the last decade,... Read more
Agilent and Imperial College London Announce Collaboration Agreement Agilent Measurement Suite to provide researchers with greater experimental freedom SANTA CLARA, Calif., February 28, 2018 Agilent Technologies Inc. (NYSE: A) and Imperial College London today signed a strategic scientific collaboration agreement that brings together Agilent’s leading analytical technologies with Imperial’s outstanding researchers. Under the agreement, Agilent... Read more
Milwaukee (July 31, 2017) – GE Healthcare announced today that it has licensed Computed Tomography (CT) organ dosimetry technology developed at Duke University. The technology enables automatic calculation of organ dose, helping the clinician to better estimate the radiation exposure to the patient https://www.genewsroom.com/press-releases/ge-healthcare-license-duke-universitys-ct-organ-dosimetry-technology Read more
“This technology assesses organ doses in patients undergoing CT in an examination-specific manner, where granular dose estimates are precisely informed by the patient anatomy and the exact irradiation condition,” said Ehsan Samei, a professor of radiology, physics and biomedical engineering at Duke, who led development of the tool. “The technology includes a realistic estimation of... Read more
Basel, 14 February 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris Pemphigus vulgaris (PV) is a life-threatening, autoimmune condition with limited treatment options1 The FDA previously granted Breakthrough Therapy Designation and Orphan Drug Designation for MabThera/Rituxan in PV Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food... Read more
FRANKLIN LAKES, N.J., Feb. 13, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pre-market approval from the U.S. Food and Drug Administration (FDA) for the BD Onclarity™ HPV assay. The test detects 14 types of high-risk human papillomavirus (HPV) from specimens collected... Read more
Basel, 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical outcomes were... Read more
Agilent Announces Scientific Collaboration with the University of Southern California Collaboration aims to facilitate transformational biomedical science and engineering research SANTA CLARA, Calif., Jan. 29, 2018 Agilent Technologies Inc. (NYSE: A) today announced that it has formed a strategic scientific collaboration with the University of Southern California (USC) Michelson Center for Convergent Bioscience to create... Read more
Basel, 29 January 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder Balovaptan has the potential to be the first pharmacotherapy to help improve core social interaction and communication in people with autism spectrum disorder Second FDA Breakthrough Therapy Designation for a Roche neuroscience medicine Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more